Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade C 113.87 1.43% 1.61
SGEN closed up 1.43 percent on Friday, December 13, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
See historical SGEN trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.43%
Lower Bollinger Band Touch Weakness 1.43%
Oversold Stochastic Weakness 1.43%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.27%
Outside Day Range Expansion 2.27%
Down 3 Days in a Row Weakness 2.27%
Oversold Stochastic Weakness 2.27%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.09%
Doji - Bullish? Reversal -0.09%
Older signals for SGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Medicine Biotechnology Cancer Treatment Of Cancer Chemotherapy Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Seattle Genetics Therapies For Cancer Non Hodgkin Lymphoma Renal Cell Carcinoma Adc Metastatic Pancreatic Cancer Castration Resistant Prostate Cancer Cd30 Hodgkin Lymphoma

Is SGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 122.36
52 Week Low 51.5
Average Volume 1,091,202
200-Day Moving Average 80.42
50-Day Moving Average 105.44
20-Day Moving Average 117.30
10-Day Moving Average 115.46
Average True Range 3.00
ADX 35.89
+DI 21.34
-DI 22.33
Chandelier Exit (Long, 3 ATRs ) 113.37
Chandelier Exit (Short, 3 ATRs ) 117.52
Upper Bollinger Band 123.32
Lower Bollinger Band 111.29
Percent B (%b) 0.21
BandWidth 10.26
MACD Line 1.94
MACD Signal Line 3.63
MACD Histogram -1.6882
Fundamentals Value
Market Cap 16.28 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -79.63
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 118.64
Resistance 3 (R3) 118.44 116.65 117.85
Resistance 2 (R2) 116.65 115.44 116.75 117.58
Resistance 1 (R1) 115.26 114.68 115.96 115.46 117.31
Pivot Point 113.47 113.47 113.82 113.57 113.47
Support 1 (S1) 112.08 112.26 112.78 112.28 110.43
Support 2 (S2) 110.29 111.50 110.39 110.16
Support 3 (S3) 108.90 110.29 109.90
Support 4 (S4) 109.10